Boards Approve One Strategy and Fund Another
Edition 3: Capital allocation is the strategy a company actually has. Most boards never test whether it matches the one they approved.
In 1985, Andy Grove and Gordon Moore took Intel out of memory chips, the business on which the company had been founded, and staked its future on microprocessors. It is remembered as one of the great strategic decisions. What is less often remembered is that by the time the two men made it, much of it had already happened. For months, the production planners and finance staff who sat in Intel’s endless capacity-allocation meetings had been shifting manufacturing resources from the loss-making memory business to the profitable microprocessor business, not because of any strategic direction from senior management, but through daily decisions driven by a simple margin rule. Robert Burgelman’s study of the exit, published in Administrative Science Quarterly, found that Intel’s internal allocation process moved scarce manufacturing capacity out of memory before the corporate strategy was officially changed. Grove later conceded that while the leadership argued over how to fight an unwinnable war, people lower in the organisation had already positioned the company for the turn. The lesson has aged well, and it is a board-level lesson: strategy is decided where capital is allocated, and the formal strategy frequently does no more than ratify what the money has already done.
Most capital is allocated by precedent, not by strategy
If capital allocation is where strategy is actually decided, the uncomfortable finding is that in most companies it is barely a decision at all. In the most rigorous study of the question, McKinsey’s Stephen Hall and Reinier Musters, with Dan Lovallo of the University of Sydney, examined more than 1,600 US companies between 1990 and 2005. The mean correlation between the capital a business unit received in one year and the next was 0.92. For a third of the business units in the sample, it was 0.99: allocations were, in effect, fixed. The vast machinery of strategic planning, the away-days, the scenario work, the board approval, produced almost no movement in where the money went. The cost of that inertia is measurable. Companies that actively reallocated capital were worth an average of 40 per cent more after fifteen years than those that let allocations ride. The scale involved is easy to underestimate: the capital allocated within multibusiness companies during the study period ran to roughly $640 billion a year, more than was raised through equity and corporate debt combined. Internal allocation is the largest capital market most boards will ever oversee, and the least examined. The cost of misallocating it never appears as a line item, because opportunity cost is invisible on an income statement. It surfaces a decade later as lost position and a valuation discount, usually charged to a different chief executive.
Why the money does not move
The inertia is not carelessness; it is produced by mechanisms any director will recognise. The budget baseline does most of the damage. Last year’s number is the anchor, the negotiation concerns the delta, and a genuinely zero-based question about whether a business deserves its capital is never actually put. Fairness norms do the rest: spreading capital evenly across divisions avoids a difficult argument, so the peanut butter gets spread. The politics are sharper still. Because executives compete for resources, a unit leader who receives less capital than last year is read, inside the company, as losing, whatever the logic for the corporation as a whole. Add the sunk-cost defence of legacy assets by the people who built their careers on them, and an annual cycle that treats allocation as a scheduling exercise, and the result is a system in which the strategy can change while the funding pattern does not.
Yet strategy is always an exercise in choice: the commitment of scarce resources to some outcomes at the expense of others. Doing more of one thing means doing less of something else, and capital allocation is where that trade either happens or quietly fails to. In this arena, actions speak louder than words: the strategy document records what a company intends, while the allocation map records what it has chosen. This is the test boards should apply to any strategy they approve: has anything scarce actually moved? Capital, manufacturing capacity, senior talent. A strategy that changes no allocation is not a strategy; it is a statement of intent. Most boards read the strategy document closely and the allocation map rarely, which means they scrutinise the plan’s numbers without ever asking whether the funding pattern gives the plan any chance of happening.
Someone always runs the capital test
When a board does not test whether its capital and its strategy match, the test still gets run. It is simply run later, by someone else, in public. BP is the sector’s current exhibit. In 2020, the board adopted one of the most ambitious strategies in the industry: cut oil and gas production by 40 per cent by 2030 and build 50 gigawatts of renewable generation. The capital followed the strategy; transition spending was guided at more than $5 billion a year. The returns did not follow the capital. BP’s share price was essentially flat from the start of 2022 to early 2025, while Shell’s rose roughly 72 per cent, and the underperformance created the opening for Elliott Management to build a stake of around 5 per cent, worth some $3.8 billion. Elliott’s demands were concrete: cut spending, strip out further structural costs, and exit the less profitable ventures, renewable power generation among them. The reset came in February 2025. Oil and gas investment was raised to around $10 billion a year, transition capex was cut by more than $5 billion a year to between $1.5 and $2 billion, production targets were rebuilt to 2.3 to 2.5 million barrels a day by 2030, and $20 billion of divestments were targeted by 2027. The chairman announced his departure within weeks. Even then, Elliott pressed for more: capital expenditure of $12 billion a year rather than BP’s planned $13 to 15 billion, and free cash flow of $20 billion by 2027 against management’s own target of $14 billion. Whether BP’s original strategy was right for the energy transition is a separate debate, and a live one. What matters for boards is who performed the test. Elliott’s campaign was, in essence, the capital test run from outside: place the allocation map next to the returns, conclude that the strategy and the money could not both be right, and force the board to say which. BP’s board did eventually answer the question. The timing, the terms, and much of the answer were chosen by someone else.
The capital test
The discipline itself is not complicated, which is precisely why its absence is a governance failure rather than a technical one. At least once a year, the board should see the allocation map beside the approved strategy: capital expenditure, operating spend, and senior talent by business, this year against last year against what the strategy implies. The chief financial officer should own the bridge between them. If the strategy names three priorities, the board should be able to see, on one page, where the money for each is coming from and what is being starved to provide it. The reallocation rate belongs on the board’s standing metrics. McKinsey’s practical suggestion is to measure the correlation between the share of resources each part of the portfolio received this year and in prior years; companies that do so are routinely surprised to find the answer well above 90 per cent. A board that tracks that number over time knows whether its strategy is being funded or merely filed. Divestment deserves a place on the agenda as often as investment, with the standing question of which businesses would not receive their capital if the proposal were made fresh today. And the board should scrutinise the delta rather than the total, because totals reassure while deltas reveal, and it should challenge the quiet asymmetry by which maintenance capital for legacy businesses sails through while investment behind the new strategy faces a business-case gauntlet. None of this requires a new committee. It requires a changed agenda and one new reporting demand.
The Intel story is usually told as a study in leadership courage, and it was that. For a board, it is more useful as evidence of where strategy actually lives. Grove and Moore’s decision mattered because it brought the official strategy into line with what the allocation process had already worked out. Most companies suffer the opposite condition: an official strategy pointing one way while the allocation process rolls the past forward at a correlation of 0.92. The board that insists on reading the allocation map is reading the strategy the company actually has. The board that reads only the deck is overseeing commentary.
If this is the level of scrutiny you want to bring to your board’s strategy work, subscribe to Strategy in the Boardroom. I write for directors, executives, and advisers who believe strategy is a discipline the board must own, and few disciplines reveal more than the capital test: whether the money, the capacity, and the talent match the strategy the board approved. Future editions will keep working through the questions of advantage, allocation, and challenge that boards cannot afford to delegate.